Telix Pharmaceuticals and ITM Isotope have agreed to combine, with Telix paying USD 1.65 billion upfront in a cash-free, debt-free transaction and up to USD 700 million more in regulatory and sales milestones for ITM-11, a carrier-free lutetium-177 edotreotide targeting somatostatin receptors in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Post-deal Telix shareholders hold about 76.3% and ITM holders about 23.7% of the combined company, marrying Telix's commercial footprint, three marketed radiopharmaceuticals and five Phase III assets with ITM's therapeutic isotope supply of lutetium-177, actinium-225 and terbium-161, a vertical chain that matters because radioisotope access, not just molecule design, often gates radioligand scaling.

The strategic logic is integration: ITM-11's Phase III COMPETE data showed 23.9 months progression-free survival (PFS) versus 14.1 months for everolimus, hazard ratio  (HR) 0.67, while overall survival (OS) was 63.4 versus 58.7 months, supporting a US filing against Novartis' Lutathera and Curium's newly approved Bexlutry.